Jiuzhou Pharmaceuticals (603456.SH) subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA.

Smart Finance News App, Jiuzhou Pharmaceutical (603456.SH) announced that its subsidiary, Ruibo (Suzhou) Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruibo Suzhou"), underwent an on-site inspection by the Food and Drug Administration (FDA) of the United States for cGMP (Current Good Manufacturing Practice) from May 19, 2025, to May 22, 2025. The inspection scope covered six main systems, including quality systems, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, Ruibo Suzhou received the Establishment Inspection Report (EIR) issued by the FDA, indicating that Ruibo Suzhou has passed the cGMP on-site inspection.